# Proxygen

Source: https://onco.cc/companies/proxygen/  
OnCo record `proxygen` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Proxygen is a Vienna company that hunts for molecular glues, small molecules that make cells destroy cancer-driving proteins. Its two lead programmes, against p300 and CDK12, are still in the laboratory.

## Summary

Proxygen is a Vienna biotechnology company founded from the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences (founders include Georg Winter and Giulio Superti-Furga) that discovers molecular glue degraders and, since April 2026, broader induced proximity therapeutics. Its most advanced programme is a first-in-class oral p300 glue degrader with sub-nanomolar potency and covalent glue pharmacology, aimed at transcription-driven cancers such as prostate, lung and bladder cancer and at CBP-mutant tumours with a synthetic lethal dependence on p300. The second lead, a brain-penetrant CDK12 glue degrader, is directed at aggressive HER2-driven cancers and tumours with central nervous system involvement. Both are preclinical, with development candidate nomination and IND-enabling studies planned over the following 12 to 18 months.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- HQ: Vienna
- Type: biotech
- Website: https://proxygen.com/

## Notes

- No financing announcement or pharma collaboration terms (for example the reported Merck deals) could be fetched from the company's news pages, so funding and investors are empty. Founding year not sourced.

## Sources

- Official website: https://proxygen.com/
- Pipeline and beyond: https://proxygen.com/pipeline-beyond
- Platform expansion announcement (April 2026): https://proxygen.com/chronicle?post=532

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/), [HER2-positive breast cancer](https://onco.cc/cancers/breast-her2-positive/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Prostate cancer](https://onco.cc/cancers/prostate/)
- fronts: [Epigenetic & Transcriptional Therapy](https://onco.cc/fronts/epigenetics/), [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- technologies: [Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET)](https://onco.cc/technologies/epigenetic-drugs/), [PROTACs & molecular glues (targeted protein degradation)](https://onco.cc/technologies/protac-degrader/)

---
JSON: https://onco.cc/api/v1/entities/proxygen.json